The FDA did not lose a neutral referee; it lost its most visible brake on accelerated biologics approvals. What follows Prasad is unlikely to be more skeptical of industry timelines.
Prasad leaves CBER after repeated clashes with sponsors
wbur.org and NPR affiliates reported on March 10, 2026, that Vinay Prasad will leave his post as director of the FDA Center for Biologics Evaluation and Research at the end of April 2026. Reuters reported the same timeline on March 6, 2026, quoting FDA Commissioner Marty Makary framing the move as the end of a planned one-year leave from the University of California, San Francisco. That official line sits awkwardly next to the record STAT and AP assembled: under Prasad, CBER rejected or stalled multiple cell and gene therapies and fought publicly with UniQure over a Huntington’s program and with Moderna over an mRNA flu application, with CNBC and others documenting a reversal after outcry when the agency initially refused even to review Moderna’s filing.
Industry had already labeled his division a choke point
ContagionLive and STAT summarized company complaints that Prasad’s division created regulatory uncertainty by demanding trials sponsors believed had been squared away in prior FDA meetings. AP News tied the same stretch to biotech equity moves and to a broader chill on rare-disease programs. When the person who says no steps off the org chart, the default bias shifts toward yes or toward negotiated post-market commitments that keep pipelines moving.
What This Actually Means
Makary’s successor pick will face the same HHS pressure Prasad navigated, but without Prasad’s public appetite for conflict with sponsors. The plausible near-term outcome is not better science; it is fewer public fights and more approvals that match what companies already promised their investors.